|

Allo-QuadCAR01-T Clinical Trials

1 actively recruiting trial

Pipeline

Phase 1/2: 1

Top Sponsors

  • AvenCell Therapeutics, Inc.1

Indications

  • Lymphoma Receiving CAR-T Therapy1
  • Leukemia Relapse1
  • Leukemia and Lymphoma1
  • Lymphoma Diffuse Large B-cell1
  • Cancer1

Other1 trial

Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies
Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.